Pascal Birman, MD
Genfit
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Pascal Birman, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:58 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04171752 · Elafibranor Pharmacokinetic Parameters in Elderly Healthy VolunteersGenfit · completed · Geriatrics, Healthy · study director
- Ph1NCT03985969 · Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and IndomethacinGenfit · completed · Drug-drug Interaction · study director
- Ph2NCT03953456 · Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)Genfit · terminated · Non-Alcoholic Fatty Liver · study director
- Ph1NCT03844555 · Elafibranor Pharmacokinetic Parameters in Renal Impaired PatientsGenfit · completed · Renal Impairment, Renal Insufficiency, Kidney Diseases · study director
- Ph1NCT03765671 · Elafibranor Pharmacokinetic Parameters in Hepatic Impaired PatientsGenfit · completed · Hepatic Impairment, Liver Disease, Pharmacokinetics · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.